MedTrace Logo

Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

NCT03443973 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 975

Last updated 2024-01-17

Study results available
· View outcomes & findings →

Summary

This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of gantenerumab versus placebo in participants with early (prodromal to mild) AD. All participants must show evidence of beta-amyloid pathology. Eligible participants will be randomized 1:1 to receive either subcutaneous (SC) injection of gantenerumab or placebo. The primary efficacy assessment will be performed at the end of the double blind period at week 116. Participants will then be offered to enter into an open-label extension (OLE). Participants not willing to go to the OLE will participate in a long term follow-up period for up to 50 weeks after the last gantenerumab dose.

Conditions

  • Alzheimer Disease

Interventions

DRUG

Gantenerumab

Gantenerumab will be administered as per the schedule specified in the respective arm.

DRUG

Placebo

Placebo matching to gantenerumab will be administered as per the schedule specified in the respective arm.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-22
Primary Completion
2022-09-23
Completion
2022-11-28
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Belgium
  • Chile
  • Croatia
  • Denmark
  • Finland
  • Japan
  • Mexico
  • Netherlands
  • Poland
  • Portugal
  • Puerto Rico
  • Singapore
  • South Korea
  • Spain
  • Sweden
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03443973 on ClinicalTrials.gov